New drug cocktail shows promise against aggressive breast cancer
NCT ID NCT01730833
First seen Jun 22, 2026 · Last updated Jun 22, 2026
Summary
This study tested a combination of two targeted antibodies (pertuzumab and trastuzumab) plus a chemotherapy drug (nab-paclitaxel) in 63 patients with HER2-positive advanced breast cancer. The goal was to see if this triple therapy could shrink tumors or delay the cancer from getting worse. The results help researchers understand how well this approach works for controlling the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Antelope Valley
Lancaster, California, 93534, United States
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
City of Hope- South Pasadena Cancer Center
South Pasadena, California, 91030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pertuzumab, trastuzumab, and nab-paclitaxel
What this could lead to
If successful, this combination could offer a more effective treatment option for people with HER2-positive advanced breast cancer, potentially delaying disease progression.
What could go wrong
This is a phase II trial with only 63 participants, so results are preliminary. The combination may cause side effects from chemotherapy and antibodies, and not all patients may respond.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.